American Society of Tropical Medicine and Hygiene (ASTMH), 65th Annual Meeting
DNDi presented in symposia on sleeping sickness and Chagas disease, they also co-authored poster presentations on filarial diseases.
DNDi Symposia
Date: November 15
Approaches, advances and needs for the elimination of human African trypanosomiasis (HAT)
Chair: Gerardo Priotto, Department of Control of Neglected Tropical Diseases, WHO
Co-chair: Crispin Lumbala, PNLTHA
| How can we achieve HAT elimination by 2020? Gerardo Priotto, Department of Control of Neglected Tropical Diseases, WHO |
| Diagnosis of HAT: New tools in a changing context Veerle Lejon, Institut de Recherche pour le Développement |
| Clinical development of new oral treatments for HAT Antoine Tarral, DNDi |
| Human African Trypanosomiasis – A bio-centric hit to lead approach to identify new lead series Thierry Diagana, Head of the Novartis Institute for Tropical Diseases |
Recent advances in the development of new treatments for chronic Chagas disease
Chair: Sergio Sosa Estani Director, Fatala Chaben Institute, Argentina
Co-chair: Isabela Ribero, Head of Chagas Clinical Program, DNDi, Geneva
| Review of recent preclinical information and pharmacokinetic-pharmacodynamic data in Chagas disease Isabela Ribero, DNDi, Geneva |
| Biological markers of therapeutic response in Chagas disease – new developments Igor Almeida, University of Texas El Paso, El Paso, United States |
| New treatment regimens of benznidazole – preclinical results and overview of planned studies Joaquin Gascon, IS Global Barcelona Institute for Global Health, Barcelona, Spain |
| Nifurtimox for Chagas disease – recent clinical studies and perspectives Jaime Altcheh, Hospital de Niños Ricardo Gutierrez, Buenos Aires, Argentina |
Chagas Coalition Symposium
Bridging the gap between patients and access to Chagas treatment: Lessons learned from scaling-up models in Latin America and the USA
Date: November 16
Chair: Peter Hotez, Baylor College of Medicine, Texas
| Why treating Chagas should be a priority? Which are the access barriers to overcome? Rafael Vilasanjuan, Barcelona Institute for Global Health |
| Chagas disease a global health problem in the USA: Gaps and challenges Sheba Meymandi, Olive View, University of California, Los Angeles, Medical Center |
| Scaling up access to treatment: Lessons learned in endemic and non-endemic countries Carolina Batista, DNDi, Rio |
| Scaling up access in Bolivia, the country with highest prevalence Joaquin Gascon, IS Global Barcelona Institute for Global Health, Barcelona, Spain |
Poster Sessions
Date: November 15
| Identification of new macrofilaricidal compounds for treatment of Onchocerciasis Hübner MP, Hoerauf A, Townson S, Gokool S, Martin C, Chojnowski A, Kreiss T, Prorok M, Siekierka J, Khetani V, Zeldis J, Canan S, Scandale I, Hawryluk N |
| Impact of ivermectin mass treatment on the burden of onchocercal skin and eye disease: detailed model predictions through to 2025 Vinkeles Melchers NVS, Coffeng LE, Murdoch ME, Bakker R, Ozoh GA, Pedrique B, de Vlas SJ, Stolk WA |
Date: November 16
| LB-5386 – Re-analysis of a sequential three-arm randomized trial of AmBisome in combination with sodium stibogluconate or miltefosine, and miltefosine monotherapy, for African visceral leishmaniasis Alexander ND, Allison A, Edwards T, Omollo R, Magirr D, Alves F, Musa A, Wasunna M |
More information:
